GZ21T as an emerging topical dermatologic therapy: A literature review
Dermatology Online Journal · 06.07.2026 · 32 (3)
DOI: 10.25251/nke1113l ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Dermatology Online Journal, online erschienen am 06.07.2026. Verfasst von Kritin K Verma und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. Hauptthemen laut MEDLINE: Keratosis, Actinic, Mycosis Fungoides, Dermatitis, Atopic, Skin Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic and treatment-resistant dermatologic disorders remain difficult to manage with current therapies because of incomplete efficacy, tolerability limitations, and long-term safety concerns. GZ21T is a topical formulation of curcumin, harmine, and isovanillin that has emerged as a potential novel therapy for inflammatory and neoplastic skin disease.
Objective
To review the preclinical evidence, proposed mechanism of action, safety data, and future clinical potential of GZ21T in atopic dermatitis, mycosis fungoides, and actinic keratoses.
Methods
A focused literature review was performed using published preclinical and early translational studies evaluating GZ17-6.02 and topical GZ21T in dermatologic disease models, including atopic dermatitis, mycosis fungoides, and actinic keratoses. Studies were included if they reported mechanistic, efficacy, or safety outcomes relevant to dermatologic application; non-dermatologic studies were used selectively to contextualize safety and pharmacology.
Results
Across preclinical models, topical GZ21T reduced inflammation, pruritus, lesion burden, and tumor growth while promoting autophagy and suppressing pro-survival signaling pathways including MAPK, PI3K-AKT, mTOR-related pathways, Wnt, and ERBB signaling. In mycosis fungoides models, GZ17-6.02 increased apoptosis and enhanced tumor cell killing, including in combination with standard agents such as bexarotene. Safety data to date suggest favorable local tolerability, minimal systemic absorption in preclinical topical studies, and reversible liver enzyme elevations in oral phase 1 testing of GZ17-6.02.
Conclusion
GZ21T represents a promising topical, multimodal therapeutic approach for inflammatory and premalignant or malignant skin disease. Further clinical studies are needed to confirm efficacy, define long-term safety, and establish its role relative to current standard therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
- School of Medicine, University of California Riverside, Riverside, CA, USA.
- MountainView Regional Medical Center, Las Cruces, NM, USA.
- Genzada Pharmaceuticals USA, Inc., Hutchinson, KS, USA.
- Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Zitieren
APA
Verma, K. K., Salas, J., Zambrano, A., & West, C. E. (2026). GZ21T as an emerging topical dermatologic therapy: A literature review. Dermatology Online Journal, 32(3). https://doi.org/10.25251/nke1113l
Vancouver
Verma KK, Salas J, Zambrano A, West CE. GZ21T as an emerging topical dermatologic therapy: A literature review. Dermatology Online Journal. 2026;32(3). doi:10.25251/nke1113l
BibTeX
@article{Verma2026,
author = {Verma, Kritin K and Salas, Jesse and Zambrano, Angelica and West, Cameron E},
title = {GZ21T as an emerging topical dermatologic therapy: A literature review},
journal = {Dermatology Online Journal},
year = {2026},
volume = {32},
number = {3},
doi = {10.25251/nke1113l}
}
EUVIMED